RxDoctor Payments Data

David Holmes

Nurse Practitioner · Waterford, MINPI 1528583325

Payments from drug & device makers

$1,211in general payments, 2019–2025

Across 50 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$301
  • Alkermes, Inc.$297
  • AbbVie$132
  • Neurocrine Biosciences, Inc.$116
  • Johnson & Johnson$100
  • Atricure, Inc.$76
  • plus $187 from 6 others

What the payments were for

  • Food & beverage$1,211100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,211 in reported general payments places this provider in the 80th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$4,595
Medicare patients
35
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate79$232,222
IngrezzaValbenazine Tosylate14$114,725
Abilify MaintenaAripiprazole39$109,208
VraylarCariprazine Hcl61$85,257
Austedo XrDeutetrabenazine35$82,698
ZyprexaOlanzapine11$21,990
Lurasidone Hcl30$6,291
Paliperidone ErPaliperidone30$4,282
Divalproex Sodium ErDivalproex Sodium84$4,187
Clozapine46$4,141
Aripiprazole81$4,068
Haloperidol69$3,102
Duloxetine Hcl92$1,863
Oxcarbazepine26$1,829
Quetiapine Fumarate154$1,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$100$232,22279 claims
Neurocrine Biosciences, Inc.Ingrezza$116$114,72514 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$27$109,20839 claims
AbbVieVraylar$132$85,25761 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$40$82,69835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Waterford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →